Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidinediones (TZDS)

Canadian Journal of Clinical Pharmacology

Volumn 15, Issue 1, 2008, Pages

  Dorais, Marc ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diabetes; Restricted drugs; TZDs

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TOLBUTAMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONFIDENCE INTERVAL; DRUG FORMULARY; DRUG MEGADOSE; FEMALE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; REIMBURSEMENT; RISK FACTOR; SOCIAL STATUS;

EID: 38549084629     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Régie de l'assurance maladie du Québec. Liste de médicaments. http://www.ramq.gouv.qc.ca/fr/professionnels/listemed/pdf/ modification/liste_medicaments.zip Accessed November 22, 2006.
2. Yki-Jarvinen H. Drug therapy: Thiazolidinediones. New England Journal of Medicine 2004;351(11):1106-1118.
3. Cheng AY, Fantus IG. Thiazolidinedione-induced congestive heart failure. Annals of Pharmacotherapy 2004;38(5):817-820.
4. Vonkorff M, Wagner EH, Saunders K. A Chronic Disease Score from Automated Pharmacy Data. Journal of Clinical Epidemiology 1992;45(2):197-203.
5. Tamblyn R, Lavoie G, Petrella L, Monette J. The Use of Prescription Claims Databases in Pharmacoepidemiologic Research - the Accuracy and Comprehensiveness of the Prescription Claims Database in Quebec. Journal of Clinical Epidemiology 1995;48(8):999-1009.
6. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350:979-982.
7. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications. JAMA 1998; 279(18):1458-1462.
8. Rahme E, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen. Arthritis & Rheumatism 2000;43[4]:917-921.